An analysis of the American Heart Association's COVID-19 Cardiovascular Disease Registry found 1 in 20 patients hospitalized with COVID-19 developed new-onset Afib.
Researchers from the University of Texas examined nearly 28,000 patients without a history of Afib who developed the condition during hospitalization.
Patients who developed Afib experienced longer hospital stays and greater need for ICU care and intubation. Approximately forty-five percent died in the hospital. The findings suggest that developing Afib is a marker of adverse clinical factors.